232 related articles for article (PubMed ID: 25376372)
1. Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice.
Shimizu R; Kitade M; Kobayashi T; Hori S; Watanabe A
J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):67-77. PubMed ID: 25376372
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic modeling for hepatic delivery and efficacy of antisense oligonucleotides with lipophilic ligands in mice.
Watanabe A; Katsube T
Biopharm Drug Dispos; 2021 Apr; 42(4):178-187. PubMed ID: 33724506
[TBL] [Abstract][Full Text] [Related]
3. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
4. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
6. Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice.
Bell TA; Brown JM; Graham MJ; Lemonidis KM; Crooke RM; Rudel LL
Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1814-20. PubMed ID: 16675724
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.
Shemesh CS; Yu RZ; Gaus HJ; Seth PP; Swayze EE; Bennett FC; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Aug; 26(4):223-35. PubMed ID: 27031383
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.
Lee RG; Fu W; Graham MJ; Mullick AE; Sipe D; Gattis D; Bell TA; Booten S; Crooke RM
J Lipid Res; 2013 Mar; 54(3):602-614. PubMed ID: 23220583
[TBL] [Abstract][Full Text] [Related]
10. Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1.
Pirie E; Ray S; Pan C; Fu W; Powers AF; Polikoff D; Miller CM; Kudrna KM; Harris EN; Lusis AJ; Crooke RM; Lee RG
PLoS Genet; 2018 Oct; 14(10):e1007732. PubMed ID: 30372444
[TBL] [Abstract][Full Text] [Related]
11. Gene Silencing Activity and Hepatic Accumulation of Antisense Oligonucleotides Bearing Cholesterol-Conjugated Thiono Triester at the Gap Region.
Nakajima M; Kasuya T; Yokota S; Onishi R; Ikehara T; Kugimiya A; Watanabe A
Nucleic Acid Ther; 2017 Aug; 27(4):232-237. PubMed ID: 28418770
[TBL] [Abstract][Full Text] [Related]
12. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.
Crooke RM; Graham MJ; Lemonidis KM; Whipple CP; Koo S; Perera RJ
J Lipid Res; 2005 May; 46(5):872-84. PubMed ID: 15716585
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide treatment produces a type I interferon response that protects against diet-induced obesity.
McCabe KM; Hsieh J; Thomas DG; Molusky MM; Tascau L; Feranil JB; Qiang L; Ferrante AW; Tall AR
Mol Metab; 2020 Apr; 34():146-156. PubMed ID: 32180554
[TBL] [Abstract][Full Text] [Related]
14. Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.
Subramanian RR; Wysk MA; Ogilvie KM; Bhat A; Kuang B; Rockel TD; Weber M; Uhlmann E; Krieg AM
Nucleic Acids Res; 2015 Oct; 43(19):9123-32. PubMed ID: 26446989
[TBL] [Abstract][Full Text] [Related]
15. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.
Geary RS; Wancewicz E; Matson J; Pearce M; Siwkowski A; Swayze E; Bennett F
Biochem Pharmacol; 2009 Aug; 78(3):284-91. PubMed ID: 19393225
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B.
Crooke ST; Geary RS
Br J Clin Pharmacol; 2013 Aug; 76(2):269-76. PubMed ID: 23013161
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
18. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.
Mullick AE; Fu W; Graham MJ; Lee RG; Witchell D; Bell TA; Whipple CP; Crooke RM
J Lipid Res; 2011 May; 52(5):885-96. PubMed ID: 21343632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
